A detailed history of Exodus Point Capital Management, LP transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 65,618 shares of RCKT stock, worth $771,667. This represents 0.01% of its overall portfolio holdings.

Number of Shares
65,618
Holding current value
$771,667
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$17.6 - $25.88 $1.15 Million - $1.7 Million
65,618 New
65,618 $1.21 Million
Q2 2023

Aug 10, 2023

SELL
$16.59 - $23.6 $4.5 Million - $6.4 Million
-271,264 Reduced 88.63%
34,798 $691,000
Q1 2023

May 11, 2023

BUY
$15.79 - $22.6 $4.83 Million - $6.92 Million
306,062 New
306,062 $5.24 Million
Q3 2022

Nov 10, 2022

BUY
$12.37 - $18.41 $244,022 - $363,174
19,727 Added 111.61%
37,402 $597,000
Q2 2022

Aug 19, 2022

SELL
$7.96 - $16.64 $22,439 - $46,908
-2,819 Reduced 13.76%
17,675 $243,000
Q1 2022

May 13, 2022

BUY
$13.16 - $23.68 $269,701 - $485,297
20,494 New
20,494 $325,000
Q1 2021

May 17, 2021

SELL
$43.34 - $65.91 $1.56 Million - $2.38 Million
-36,085 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$23.3 - $59.57 $151,822 - $388,158
6,516 Added 22.04%
36,085 $1.98 Million
Q3 2020

Nov 16, 2020

BUY
$20.5 - $28.59 $606,164 - $845,377
29,569 New
29,569 $676,000
Q1 2020

May 15, 2020

SELL
$9.71 - $25.11 $301,534 - $779,765
-31,054 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$11.07 - $24.23 $204,285 - $447,140
18,454 Added 146.46%
31,054 $707,000
Q3 2019

Nov 14, 2019

BUY
$10.85 - $14.78 $136,710 - $186,228
12,600 New
12,600 $147,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $890M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.